Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: Adaptation of an existing cohort model to the situation in the Netherlands

Cost-effectiveness analysis of Human Papillomavirus (HPV) Vaccination in the Netherlands: Recent publication reinforces favorable cost-effectiveness despite misleading conclusion

“…I conclude that the conclusion by de Kok et al is misleading, should be re-visited and would probably better be formulated as "In the Netherlands, HPV vaccination is likely to be cost-effective if compared with screening alone", and that is fully in line what other studies -with 2 of them in Vaccinerecently found [1,2,14].…”

“…As the design of the model by de Kok et al is comparable to that published by other research groups that estimated cost-effectiveness of HPV vaccination [1,2,14], comparable costeffectiveness ratios from these analyses would be expected. Indeed, if the only relevant ratio from de Kok et al at D 19,700 would be taken, the similarity is striking.…”

“…Two recent publications in Vaccine estimated potential favorable cost-effectiveness for HPV vaccination of teenage girls in the Netherlands [1,2]. Just a few months ago, de Kok et al concluded in another journal that "In the Netherlands, HPV vaccination is not cost-effective even under favorable assumptions" [3].…”

Cost-effectiveness of vaccination against meningococcal B among Dutch infants

“…4,[28][29][30][31][32][33] Our results show that routine infant vaccination against MenB-related disease is far more expensive per QALY gained than routine vaccination against MenC-related disease 13 or human papilloma virus, which was recently implemented in the Dutch national immunization program. 34 Cost-effectiveness analyses in England also indicate that vaccinating against MenB disease is cost-effective only when the vaccine is inexpensive (£7,-) using a threshold of £30,000 per QALY. 35,36 If we would calculate with same annual disease incidence, the vaccine could cost £13,-using the same threshold of the willingness to pay.…”

Economic evaluation of human papilloma virus vaccination in the European Union: a critical review

“…Thirty-six articles including EEs focused on HPV vaccination strategies were considered eligible for analysis; 20 were then excluded, as they referred to non-EU settings. Therefore, 16 articles [18,[20][21][22][23][24][25][26][27][28][29][30][31][32][33][34] were eligible. One of them lacked essential methodological transparency [20], so 15 were eventually selected comprising 24 EEs since 9 articles [21, 23-26, 30, 32-34] contained two separate analyses.…”